A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
A newly developed prediction model may be able to calculate the risk of opioid relapse among individuals in the early stages of medication treatment—as early as three weeks into therapy.
As part of a new NIH consortium, scientists will trace how regions targeted by deep brain stimulation connect with the rest of the brain, information that could improve the treatment's efficacy.
With a transformational gift of $6.5 million, the Weinberg Family Cerebral Palsy Center at Columbia University will launch its second decade of excellence in clinical care, research, and education.
Columbia bioengineers are the first to program bacteria that guide immune cells to tumors, which could make more cancers treatable with immunotherapies.
In his new role leading the Chan Zuckerberg Biohub New York, Andrea Califano will bring together scientists from several universities to engineer the immune system to detect and treat disease.
Columbia's Andrea Califano will lead the new Chan Zuckerberg Biohub New York in its mission to harness and engineer immune cells for the early detection and eradication of human disease.
A new study of sleep in women shows that delaying bedtime by just 90 minutes each night damages cells that line the blood vessels, supporting the hypothesis that poor sleep is linked to heart health.
Physician-scientist Neil Vasan brings the perspectives he's gained from classical singing and structural biology to his search for new breast cancer treatments.
Brief walks every hour can offset the harms of prolonged sitting—but who has time for that? With the help of an NPR podcast, researcher Keith Diaz is trying to identify, and break, the barriers.